CD200R Protein & Antibody

Cluster of Differentiation 200 Receptor

CD200R Products

CD200R Protein, Recombinant

Molecule	Species	Description	Cat. No
CD200R	Cynomolgus	CD200R Protein, Recombinant	11232-C08H

  11232-C08H: Immobilized Cynomolgus CD200R at 2 µg/ml (100 µl/well) can bind human CD200 with a linear ranger of 0.3125-5 ng/ml. Measured by its binding ability in a functional ELISA.

CD200R Antibody

Molecule	Application	Description	Cat. No
Cynomolgus CD200R	WB, ELISA	Rabbit Polyclonal Antibody	11232-RP01
Cynomolgus CD200R	WB, ELISA	Rabbit Polyclonal Antibody (Antigen Affinity Purified)	11232-RP02

CD200R Related Areas

Immunology>>Cluster of Differentiation>>Other>>CD200R

CD200R Background

Cluster of differentiation 200 receptor (CD200R) / OX2 is a member of the Ig supergene family that is primarily expressed on myeloid cells. CD200R / OX2 is a cell surface glycoprotein receptor interacting with CD200 in order to regulate immune responses and it is described as an inhibitory receptor capable of regulating the activation threshold of inflammatory immune responses. It has been demonstrated that the CD200R can inhibit the activation of FcepsilonRI. There are four isoforms of the family: CD200R1, CD200R2, CD200R3, and CD200R4. Unlike the most of myeloid inhibitory receptors, CD200R does not contain a phosphatase recruiting inhibitory motif. CD200 transmits an immunoregulatory signal through CD200R to mediate microglia, while activation of microglia is associated with the pathogenesis and progression of Parkinson's disease.

CD200R Related Studies

1. Zola H, et al. (2007) CD molecules 2006-human cell differentiation molecules. J Immunol Methods. 318 (1-2): 1-5.
2. Ho IC, et al. (2009) GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation. Nat Rev Immunol. 9 (2): 125–35.
3. Matesanz-Isabel J, et al. (2011) New B-cell CD molecules. Immunology Letters.134 (2): 104-12.
4. Wang XJ, et al. (2007) CD200-CD200R regulation of microglia activation in the pathogenesis of Parkinson's disease. Journal of Neuroimmune pharmacology. 2(3): 259-64.